复宏汉霖(02696)：纳武利尤单抗生物类似药HLX18(重组抗PD-1人源化单克隆抗体注射液)用于多种实体瘤治疗的1期临床试验申请获国家药监局批准

智通财经03-20

智通财经APP讯，复宏汉霖(02696)发布公告，近日，本公司自主研发的纳武利尤单抗生物类似药HLX18(重组抗PD-1人源化单克隆抗体注射液)(“HLX18”)用于多种实体瘤治疗的1期临床试验申请(IND)获国家药品监督管理局(NMPA)批准。HLX18是本公司自主研发的纳武利尤单抗生物类似药，潜在适应症包括黑色素瘤、非小细胞肺癌、恶性胸膜间皮瘤、肾细胞癌、经典型霍奇金淋巴瘤、头颈部鳞状细胞癌、...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2620782400?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-03-20 18:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2620782400","market":"us","top_or_hot":-1,"title":"复宏汉霖(02696)：纳武利尤单抗生物类似药HLX18(重组抗PD-1人源化单克隆抗体注射液)用于多种实体瘤治疗的1期临床试验申请获国家药监局批准","media":"智通财经","content":"<div>\n<p>智通财经APP讯，复宏汉霖(02696)发布公告，近日，本公司自主研发的纳武利尤单抗生物类似药HLX18(重组抗PD-1人源化单克隆抗体注射液)(“HLX18”)用于多种实体瘤治疗的1期临床试验申请(IND)获国家药品监督管理局(NMPA)批准。HLX18是本公司自主研发的纳武利尤单抗生物类似药，潜在适应症包括黑色素瘤、非小细胞肺癌、恶性胸膜间皮瘤、肾细胞癌、经典型霍奇金淋巴瘤、头颈部鳞状细胞癌、...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1416649.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>复宏汉霖(02696)：纳武利尤单抗生物类似药HLX18(重组抗PD-1人源化单克隆抗体注射液)用于多种实体瘤治疗的1期临床试验申请获国家药监局批准</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n复宏汉霖(02696)：纳武利尤单抗生物类似药HLX18(重组抗PD-1人源化单克隆抗体注射液)用于多种实体瘤治疗的1期临床试验申请获国家药监局批准\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-20 18:14 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1416649.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，复宏汉霖(02696)发布公告，近日，本公司自主研发的纳武利尤单抗生物类似药HLX18(重组抗PD-1人源化单克隆抗体注射液)(“HLX18”)用于多种实体瘤治疗的1期临床试验申请(IND)获国家药品监督管理局(NMPA)批准。HLX18是本公司自主研发的纳武利尤单抗生物类似药，潜在适应症包括黑色素瘤、非小细胞肺癌、恶性胸膜间皮瘤、肾细胞癌、经典型霍奇金淋巴瘤、头颈部鳞状细胞癌、...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1416649.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PD","symbol_name":"PagerDuty, Inc.","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1416649.html","article_id":"2620782400","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2620782400","pubTimestamp":1774001646,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，复宏汉霖 发布公告，近日，本公司自主研发的纳武利尤单抗生物类似药HLX18用于多种实体瘤治疗的1期临床试验申请获国家药品监督管理局批准。部分肿瘤细胞的PD-1配体上调，通过这个通路信号传导可抑制激活的T细胞对肿瘤的免疫监视。2025年12月， HLX18于美国获许可开展用于多种实体瘤治疗的1期临床试验。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"PD":"PagerDuty, Inc.","BK1161":"生物科技","HK0000165453.HKD":"华夏精选大中华科技基金 A类港币","LU1169590202.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"I\" (USD) ACC","BK4023":"应用软件","HK0000320223.HKD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (HKD) ACC","HK0000306701.USD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (USD) INC","HK0000320264.USD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (USD) ACC","LU1169589451.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"A\" (USD) ACC","HK0000306685.HKD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (HKD) INC","02696":"复宏汉霖"},"translate_title":"Henlius (02696): The Phase 1 clinical trial application of nivolumab biosimilar HLX18 (recombinant anti-PD-1 humanized monoclonal antibody injection) for the treatment of multiple solid tumors was approved by the NMPA","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PD":1.5,"02696":1.5},"content_text":"智通财经APP讯，复宏汉霖(02696)发布公告，近日，本公司自主研发的纳武利尤单抗生物类似药HLX18(重组抗PD-1人源化单克隆抗体注射液)(“HLX18”)用于多种实体瘤治疗的1期临床试验申请(IND)获国家药品监督管理局(NMPA)批准。HLX18是本公司自主研发的纳武利尤单抗生物类似药，潜在适应症包括黑色素瘤、非小细胞肺癌、恶性胸膜间皮瘤、肾细胞癌、经典型霍奇金淋巴瘤、头颈部鳞状细胞癌、尿路上皮癌、胃癌、胃食管连接部癌或食管腺癌、食管癌、结直肠癌、肝细胞癌等原研药已获批的适应症。T细胞中表达的PD-1受体与其配体PD-L1和PD-L2结合，可以抑制T细胞增殖和细胞因子生成。部分肿瘤细胞的PD-1配体上调，通过这个通路信号传导可抑制激活的T细胞对肿瘤的免疫监视。纳武利尤单抗是一种人类免疫球蛋白G4(IgG4)单克隆抗体 (HuMAb)，可与PD-1受体结合，阻断其与PD-L1和PD-L2之间的相互作用，阻断PD1通路介导的免疫抑制反应，包括抗肿瘤免疫反应。2025年12月， HLX18于美国获许可开展用于多种实体瘤治疗的1期临床试验。根据IQVIA MIDASTM的资料(IQVIA是全球医药健康产业专业信息和战略咨询服务提供商)，2025年度，纳武利尤单抗于全球范围内的销售额约为117.85 亿美元。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2620782400","isCrawlerRequest":true}